Omeros (NASDAQ:OMER) Given "Hold" Rating at Needham & Company LLC

Key Points

• Omeros Corporation has received a "hold" rating from Needham & Company, while D. Boral Capital and HC Wainwright maintain "buy" ratings with price targets of $36.00 and $9.00, respectively.
• The company's stock dropped 3.5% recently, closing at $4.12, significantly lower than its 52-week high of $13.60.
• Omeros reported earnings of ($0.65) EPS for the previous quarter, which missed analysts' expectations of ($0.60) EPS.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "hold" rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports.

OMER has been the subject of several other reports. D. Boral Capital restated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a report on Friday. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. Finally, Wall Street Zen lowered Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Stock Down 3.5%

NASDAQ OMER opened at $4.12 on Friday. The company has a fifty day moving average of $3.58 and a two-hundred day moving average of $5.82. The firm has a market capitalization of $254.45 million, a price-to-earnings ratio of -1.55 and a beta of 2.26. Omeros has a 52 week low of $2.95 and a 52 week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last issued its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). Equities research analysts anticipate that Omeros will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Omeros

A number of large investors have recently bought and sold shares of OMER. BNP Paribas Financial Markets boosted its position in Omeros by 548.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,272 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 21,376 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of Omeros during the 2nd quarter worth approximately $316,000. Sei Investments Co. acquired a new position in shares of Omeros during the 2nd quarter worth approximately $40,000. Marshall Wace LLP raised its stake in shares of Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company's stock worth $2,224,000 after buying an additional 97,224 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Omeros by 34.1% during the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company's stock worth $350,000 after buying an additional 29,644 shares during the period. Hedge funds and other institutional investors own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.